Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy
Renovaro Biosciences (NASDAQ:RENB) has published groundbreaking preclinical data in the journal Vaccines, validating their next-generation dendritic cell (DC) therapy platform. The study demonstrated the platform's effectiveness in treating pancreatic cancer, showing up to 81.7% reduction in tumor size in humanized mouse models.
The engineered DCs, expressing CD93, CD40L, and CXCL13, demonstrated significant anti-tumor efficacy and immune system activation. The therapy's "off-the-shelf" approach, using CD34鈦� stem cells from healthy donors, enables scalable production and cryopreservation, enhancing its clinical potential.
The company plans to expand testing across multiple tumor types and explore combination strategies with other therapies as part of their clinical development roadmap.
Renovaro Biosciences (NASDAQ:RENB) ha pubblicato dati preclinici innovativi sulla rivista Vaccines, confermando l'efficacia della loro piattaforma di terapia con cellule dendritiche (DC) di nuova generazione. Lo studio ha dimostrato l'efficacia della piattaforma nel trattamento del cancro al pancreas, con una riduzione delle dimensioni del tumore fino all'81,7% in modelli murini umanizzati.
Le DC ingegnerizzate, che esprimono CD93, CD40L e CXCL13, hanno mostrato una significativa efficacia antitumorale e attivazione del sistema immunitario. L'approccio 鈥減ronto all'uso鈥�, basato su cellule staminali CD34鈦� provenienti da donatori sani, consente una produzione scalabile e la crioconservazione, aumentando il potenziale clinico della terapia.
L'azienda prevede di ampliare i test su diversi tipi di tumore ed esplorare strategie di combinazione con altre terapie nel loro piano di sviluppo clinico.
Renovaro Biosciences (NASDAQ:RENB) ha publicado datos precl铆nicos innovadores en la revista Vaccines, validando su plataforma de terapia con c茅lulas dendr铆ticas (DC) de pr贸xima generaci贸n. El estudio demostr贸 la eficacia de la plataforma en el tratamiento del c谩ncer de p谩ncreas, mostrando una reducci贸n del tama帽o tumoral de hasta un 81,7% en modelos murinos humanizados.
Las DCs dise帽adas, que expresan CD93, CD40L y CXCL13, demostraron una eficacia antitumoral significativa y activaci贸n del sistema inmunol贸gico. El enfoque 鈥渓isto para usar鈥�, que emplea c茅lulas madre CD34鈦� de donantes sanos, permite una producci贸n escalable y criopreservaci贸n, aumentando su potencial cl铆nico.
La compa帽铆a planea ampliar las pruebas a m煤ltiples tipos de tumores y explorar estrategias combinadas con otras terapias como parte de su hoja de ruta para el desarrollo cl铆nico.
Renovaro Biosciences (NASDAQ:RENB)電� 頃欖垹歆� Vaccines鞐� 順侅嫚鞝侅澑 鞝勳瀯靸� 雿办澊韯半ゼ 氚滍憸頃橂┌ 彀劯雽� 靾橃靸侅劯韽�(DC) 旃橂 頂岆灚韽检潣 須姤鞚� 鞛呾頄堨姷雼堧嫟. 鞐瓣惮 瓴瓣臣 鞚戈皠頇� 毵堨毎鞀� 氇嵏鞐愳劀 旆岇灔鞎� 旃橂鞐� 鞛堨柎 斓滊寑 81.7% 膦呾枒 韥赴 臧愳唽毳� 氤挫榾鞀惦媹雼�.
CD93, CD40L, CXCL13鞚� 氚滍槃頃橂姅 鞙犾爠鞛� 臁办瀾霅� DC電� 臧曤牓頃� 頃鞏� 須臣鞕� 氅挫棴 鞁滌姢韰� 頇滌劚頇旊ゼ 雮橅儉雰堨姷雼堧嫟. 瓯搓皶頃� 旮办鞛愳潣 CD34鈦� 欷勱赴靹疙彫毳� 鞚挫毄頃� 鈥滌鞁� 靷毄 臧�電ロ暅鈥� 鞝戧芳氩曥潃 雽�霟� 靸濎偘瓿� 霃欔舶 氤挫〈鞚� 臧�電ロ晿瓴� 頃橃棳 鞛勳儊鞝� 鞛犾灛霠レ潉 雴掛瀰雼堧嫟.
須岇偓電� 鞛勳儊 臧滊皽 搿滊摐毵奠潣 鞚柬櫂鞙茧 雼れ枒頃� 膦呾枒 鞙犿槙鞐� 雽�頃� 韰岇姢韸鸽ゼ 頇曤寑頃橁碃 雼るジ 旃橂氩曣臣鞚� 氤戩毄 鞝勲灥霃� 氇儔頃� 瓿勴殟鞛呺媹雼�.
Renovaro Biosciences (NASDAQ:RENB) a publi茅 des donn茅es pr茅cliniques r茅volutionnaires dans la revue Vaccines, validant leur plateforme de th茅rapie par cellules dendritiques (DC) de nouvelle g茅n茅ration. L'茅tude a d茅montr茅 l'efficacit茅 de la plateforme dans le traitement du cancer du pancr茅as, avec une r茅duction de la taille tumorale allant jusqu'脿 81,7% dans des mod猫les murins humanis茅s.
Les DC modifi茅es, exprimant CD93, CD40L et CXCL13, ont montr茅 une efficacit茅 antitumorale significative et une activation du syst猫me immunitaire. L'approche 芦 pr锚te 脿 l'emploi 禄, utilisant des cellules souches CD34鈦� provenant de donneurs sains, permet une production 脿 grande 茅chelle et une cryoconservation, renfor莽ant ainsi son potentiel clinique.
L'entreprise pr茅voit d'茅tendre les essais 脿 plusieurs types de tumeurs et d'explorer des strat茅gies de combinaison avec d'autres th茅rapies dans le cadre de leur feuille de route de d茅veloppement clinique.
Renovaro Biosciences (NASDAQ:RENB) hat bahnbrechende pr盲klinische Daten in der Fachzeitschrift Vaccines ver枚ffentlicht, die ihre Plattform f眉r dendritische Zelltherapien (DC) der n盲chsten Generation validieren. Die Studie zeigte die Wirksamkeit der Plattform bei der Behandlung von Bauchspeicheldr眉senkrebs mit einer Reduktion der Tumorgr枚脽e um bis zu 81,7% in humanisierten Mausmodellen.
Die gentechnisch ver盲nderten DCs, die CD93, CD40L und CXCL13 exprimieren, zeigten eine signifikante antitumorale Wirksamkeit und Aktivierung des Immunsystems. Der 鈥濷ff-the-Shelf鈥�-Ansatz der Therapie, der CD34鈦� Stammzellen von gesunden Spendern verwendet, erm枚glicht eine skalierbare Produktion und Kryokonservierung, was das klinische Potenzial erh枚ht.
Das Unternehmen plant, die Tests auf verschiedene Tumorarten auszuweiten und Kombinationsstrategien mit anderen Therapien im Rahmen ihres klinischen Entwicklungsplans zu erforschen.
- None.
- Still in preclinical stage, requiring extensive clinical trials before potential approval
- Competition in solid tumor space is intense
- Additional studies and combination strategies needed before clinical implementation
Insights
Renovaro's engineered dendritic cell therapy shows remarkable 81.7% tumor reduction in preclinical models, validating their platform technology for potential clinical applications.
The peer-reviewed publication in Vaccines represents a significant validation milestone for Renovaro's dendritic cell (DC) therapy platform. The study demonstrates that their genetically engineered DCs expressing CD93, CD40L, and CXCL13 reduced pancreatic tumor burden by up to
What makes this approach scientifically noteworthy is the specific genetic modifications to these dendritic cells. By engineering expression of CD93 (involved in immune cell adhesion), CD40L (a potent T-cell co-stimulator), and CXCL13 (a chemokine that attracts B cells), Renovaro has created DCs with enhanced ability to activate multiple arms of the immune system. The data showing increases in both CD4+ helper T cells and cytotoxic CD8+ T cells indicates successful priming of both branches of adaptive immunity.
Particularly promising is the platform's allogeneic approach, using CD34+ stem cells from healthy donors to generate "off-the-shelf" therapies. This circumvents the manufacturing complexity and time constraints of autologous cell therapies, which require processing each patient's own cells. The cryopreservation capability further enhances clinical practicality.
While these results are encouraging, it's important to note these remain preclinical findings. The translation from humanized mouse models to human patients often sees efficacy reductions. Additionally, pancreatic cancer's dense stromal environment creates significant barriers to immune cell infiltration that may not be fully recapitulated in these models. The company's planned exploration of combination approaches with checkpoint inhibitors suggests recognition of these potential limitations.
Renovaro's preclinical data validates their engineered DC platform, strengthening their competitive position in the challenging solid tumor immunotherapy space.
This peer-reviewed publication significantly enhances Renovaro's scientific credibility and intellectual property position in the competitive cell therapy landscape. The company is addressing several critical limitations that have historically challenged dendritic cell therapies.
First, by using an allogeneic approach derived from CD34+ stem cells, Renovaro potentially solves the manufacturing scalability issues that have hampered previous DC therapies. Traditional dendritic cell approaches like Provenge required complex, patient-specific manufacturing processes that limited commercial viability. An "off-the-shelf" approach could dramatically improve cost structure and market accessibility.
Second, the genetic engineering approach targeting CD93, CD40L, and CXCL13 demonstrates sophisticated immunological understanding. This multi-faceted activation strategy could potentially overcome the immunosuppressive tumor microenvironment that has limited efficacy of previous immunotherapies in pancreatic cancer 鈥� a massive unmet medical need with a market potential exceeding
The platform nature of this technology is particularly valuable from an investment perspective. Rather than a single-product company, Renovaro appears positioned to potentially address multiple solid tumor indications, enhancing their pipeline opportunities. The mention of future AI-based antigen discovery suggests a technology roadmap that could extend their competitive moat.
While still preclinical, these results represent meaningful de-risking of Renovaro's platform. The publication timing is favorable as investors increasingly focus on solid tumor cell therapies beyond CAR-T approaches. The company's planned expansion into combination therapies with checkpoint inhibitors and radioligand approaches aligns with current clinical development trends in oncology.
Landmark preclinical data validate Renovaro's platform representing a step forward in the fight against pancreatic and solid tumors
LOS ANGELES, CALIFORNIA / / July 17, 2025 / Renovaro Biosciences (NASDAQ:RENB), an oncology and neurology focused TechBio company, today announced the publication of a peer-reviewed study in Vaccines, a leading journal in the field of immunology. The paper details compelling preclinical data on Renovaro's next-generation dendritic cell (DC) therapy platform, showcasing its ability to significantly reduce pancreatic tumor burden and activate robust immune responses in humanized mouse models.
The published study, titled "Therapeutic Efficacy of CD34-derived Allogeneic Dendritic Cells Engineered to Express CD93, CD40L, and CXCL13 in Humanized Mouse Models of Pancreatic Cancer," represents a major milestone in validating the scientific underpinnings of Renovaro's platform. The therapy combines cutting-edge genetic engineering with an allogeneic "off-the-shelf" approach to generate highly potent DCs capable of priming the immune system against aggressive, immunoresistant tumors.
"This publication marks a critical moment for Renovaro," said David Weinstein, Renovaro's CEO. "The data clearly demonstrate the potential of our engineered dendritic cell therapy to overcome tumor-induced immunosuppression, which is one of the greatest challenges in treating pancreatic and other solid tumors. It further validates the broader capabilities of our cell engineering platform."
Key Findings from the Study Include:
Robust Anti-Tumor Efficacy: Engineered DCs expressing CD93, CD40L, and CXCL13 significantly reduced tumor weight and volume, namely up to
81.7% in humanized mouse models.Immune Activation: Treated animals showed marked increases in CD4鈦� T cells as well as cytotoxic CD8鈦� T and NK cells in blood, bone marrow, and tumor microenvironments.
Antigen-Specific Response: Activated T cells demonstrated selective cytotoxicity against pancreatic tumor cells while sparing unrelated cell types.
Scalable, Off-the-Shelf Platform: The use of CD34鈦� hematopoietic stem cells from healthy donors enables scalable production and cryopreservation of engineered DCs, enhancing clinical utility.
This research builds on Renovaro's broader strategy of developing immune-enhancing therapies that can be flexibly adapted for solid tumor indications and lays the foundation for future AI-based antigen discovery that will further specialize these medications toward specific cancer indications and patient sub-populations. The engineered DC platform complements Renovaro's growing pipeline of precision medicines.
"By demonstrating not only efficacy but also scalability and specificity, this work strengthens our competitive moat and reaffirms our position as a platform company built to deliver durable impact," added Dr. Lu Chen, Renovaro's Executive Vice President of Product Development and CMC.
Renovaro plans to initiate additional preclinical studies across multiple tumor types and explore combination strategies with checkpoint inhibitors and radioligand therapies. These efforts are part of a broader roadmap to bring this novel therapeutic platform into the clinic.
This work was performed in collaboration with immunology professor Dr. Anahid Jewett, who sadly . Her exceptional guidance and unique expertise allowed this project to progress, and the acceptance of this publication serves as further testament to her extraordinary ability as a researcher.
The full peer-reviewed article is available via Vaccines:
About Renovaro Biosciences
Renovaro (NASDAQ: RENB) is a TechBio company combining advanced machine learning with breakthrough immunotherapies to transform how cancer and other diseases are detected and treated. Through proprietary platforms in cell therapy, RNA diagnostics, and federated AI, Renovaro is pioneering scalable and personalized approaches to precision medicine.
Contact:
David Weinstein
Chief Executive Officer
[email protected]
www.renovarogroup.com
SOURCE: Renovaro Biosciences
View the original on ACCESS Newswire
FAQ
What are the key results of Renovaro's (NASDAQ:RENB) dendritic cell therapy study?
How does Renovaro's (RENB) dendritic cell therapy platform work?
What are the next steps for Renovaro Biosciences' dendritic cell therapy?
What makes Renovaro's (NASDAQ:RENB) dendritic cell therapy platform unique?
What types of cancer is Renovaro's (RENB) therapy targeting?
